Characteristics and predictive model for diffuse large B-cell lymphoma with early chemoimmunotherapy failure
IntroductionThe outcomes of refractory or relapsed diffuse large B-cell lymphoma are generally poor, especially those relapsed or progressed within 12 months from diagnosis named as early chemoimmunotherapy failure (ECF), with a 2-year OS of 24.7%. Due…